Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2012
- Debt to Equity since 2012
- Price to Operating Profit (P/OP) since 2012
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The financial data indicates noticeable fluctuations in the leverage and coverage ratios over the five-year period.
- Debt to Equity Ratio
- This ratio shows a decline from 6.58 in 2020 to 3.67 in 2022, indicating a reduction in reliance on debt compared to equity during this period. However, it increased again to 5.73 in 2023 and then sharply surged to 20.19 by the end of 2024, suggesting a significant increase in debt relative to equity in the most recent year.
- Debt to Equity Ratio (Including Operating Lease Liability)
- The trend closely mirrors the standard debt to equity ratio, with values slightly higher, ending at 20.46 in 2024. This indicates that lease liabilities contribute marginally to total debt obligations.
- Debt to Capital Ratio
- There is a gradual decline from 0.87 in 2020 to 0.79 in 2022, implying an improvement in capital structure with less debt. This ratio then rose to 0.85 in 2023 and further to 0.95 in 2024, showing increased use of debt within the capital structure towards the end of the period.
- Debt to Capital Ratio (Including Operating Lease Liability)
- The pattern remains consistent with the debt to capital ratio excluding lease liabilities, confirming that lease obligations have a minimal effect on overall capital structure.
- Debt to Assets Ratio
- This ratio steadily decreased from 0.57 in 2020 to 0.44 in 2023, reflecting a reduction in total debt relative to total assets. In 2024, the ratio increased to 0.50, indicating a slight rise in leverage from the asset perspective.
- Debt to Assets Ratio (Including Operating Lease Liability)
- The trend is similar to the standard debt to assets ratio, with slightly higher values, indicating lease liabilities moderately affect the total debt position.
- Financial Leverage
- Financial leverage decreased from 11.51 in 2020 to 8.04 in 2022, followed by a rise to 13 in 2023 and a dramatic increase to 40.65 in 2024. This spike indicates a substantial increase in assets financed by shareholders’ equity, possibly due to a significant reduction in equity or a large increase in liabilities.
- Interest Coverage Ratio
- The ratio improved considerably from 2.38 in 2020 to 7.04 in 2022, reflecting improved ability to meet interest obligations. However, it declined to 3.81 in 2023 and further down to 2.32 in 2024, suggesting a weakening capacity to cover interest expenses in the recent years.
- Fixed Charge Coverage Ratio
- The fixed charge coverage ratio follows a similar pattern as interest coverage, improving from 2.28 in 2020 to 6.54 in 2022 before dropping back to 2.24 in 2024. This pattern indicates increased financial risk related to fixed costs coverage in the later years.
Overall, the data shows a period of deleveraging and improved interest coverage from 2020 to 2022, followed by a reversal characterized by increased leverage and reduced coverage ratios from 2023 to 2024. The sharp rise in debt-related ratios and financial leverage in 2024 alongside declining coverage ratios points to increased financial risk during the most recent year.
Debt Ratios
Coverage Ratios
Debt to Equity
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt and finance lease obligations | ||||||
Long-term debt and finance lease obligations, excluding current portion | ||||||
Total debt | ||||||
Stockholders’ equity | ||||||
Solvency Ratio | ||||||
Debt to equity1 | ||||||
Benchmarks | ||||||
Debt to Equity, Competitors2 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Equity, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Equity, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals significant fluctuations over the five-year period in terms of total debt, stockholders' equity, and the debt to equity ratio.
- Total Debt
- Total debt has exhibited a decreasing trend from 2020 to 2023, starting at $86,056 million in 2020 and declining steadily each year to reach $59,385 million in 2023. However, this trend reversed in 2024, with total debt increasing to $67,144 million. Despite the uptick in the final year, the overall trend across the period was a reduction in debt, which may indicate efforts to deleverage or manage borrowings more prudently over most of the period.
- Stockholders’ Equity
- Stockholders' equity experienced growth from 2020 through 2022, rising from $13,076 million to $17,254 million, suggesting accumulation of retained earnings or additional capital contributions. In contrast, 2023 and 2024 saw a significant decline, with equity dropping sharply to $10,360 million in 2023 and further plunging to $3,325 million in 2024. This sudden decrease may raise concerns about losses, dividend distributions, or other equity-reducing events affecting the company’s net asset value.
- Debt to Equity Ratio
- The debt to equity ratio followed a generally decreasing trend from 6.58 in 2020 to 3.67 in 2022, reflecting a stronger equity base relative to debt. However, this ratio surged to 5.73 in 2023 and dramatically increased to 20.19 in 2024. The sharp increase in 2024 appears primarily driven by the substantial reduction in equity rather than just the increase in debt. Such a high leverage ratio indicates increased financial risk and potential difficulties in meeting obligations without significant equity support.
In summary, while the company showed signs of improving its financial structure in the initial years through debt reduction and equity growth, the latter two years reveal a concerning deterioration, marked by a contraction in equity and a sharp rise in leverage. This shift suggests rising financial risk and warrants further investigation into the underlying causes, such as operational performance, asset impairment, or other strategic financial decisions.
Debt to Equity (including Operating Lease Liability)
AbbVie Inc., debt to equity (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt and finance lease obligations | ||||||
Long-term debt and finance lease obligations, excluding current portion | ||||||
Total debt | ||||||
Current operating lease liabilities (included in Accounts payable and accrued liabilities) | ||||||
Noncurrent operating lease liabilities (included in Other long-term liabilities) | ||||||
Total debt (including operating lease liability) | ||||||
Stockholders’ equity | ||||||
Solvency Ratio | ||||||
Debt to equity (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Equity (including Operating Lease Liability), Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Equity (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The analysis of the annual financial data reveals several notable trends related to the company's capital structure over the five-year period ending December 31, 2024.
- Total Debt (including operating lease liability)
-
The total debt shows a general downward trend from 2020 through 2023, moving from 87,063 million USD to 60,286 million USD. This indicates a significant reduction in debt levels during these years. However, in 2024, there is an increase in total debt to 68,019 million USD, reversing the prior decline.
- Stockholders’ Equity
-
The stockholders’ equity increased steadily from 13,076 million USD in 2020 to a peak of 17,254 million USD in 2022. After 2022, equity sharply decreased, falling to 10,360 million USD in 2023 and further declining to 3,325 million USD in 2024. The pronounced drop suggests a potential erosion of shareholder value or significant changes in retained earnings or capital structure.
- Debt to Equity Ratio (including operating lease liability)
-
The debt to equity ratio decreased continuously from 6.66 in 2020 to 3.72 in 2022, reflecting a strengthening equity base relative to debt and indicating a more conservative leverage position in that period. However, in 2023, the ratio increased noticeably to 5.82 and then surged dramatically to 20.46 in 2024. This sharp increase primarily results from the simultaneous reduction in equity and the rebound in debt, signifying a highly leveraged financial position by the end of 2024.
In summary, the data portrays a company that initially reduced its leverage and improved equity levels until 2022, followed by a period of deteriorating equity and increased leverage, culminating in a significantly elevated debt to equity ratio by 2024. These changes may indicate increased financial risk and warrant further investigation into the underlying causes.
Debt to Capital
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt and finance lease obligations | ||||||
Long-term debt and finance lease obligations, excluding current portion | ||||||
Total debt | ||||||
Stockholders’ equity | ||||||
Total capital | ||||||
Solvency Ratio | ||||||
Debt to capital1 | ||||||
Benchmarks | ||||||
Debt to Capital, Competitors2 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Capital, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Capital, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The analysis of the financial data over the five-year period reveals several notable trends related to the company's debt and capital structure.
- Total Debt
- The total debt exhibits a decreasing trend from 2020 through 2023, moving from $86,056 million down to $59,385 million. However, there is a reversal of this trend in 2024, with total debt increasing to $67,144 million.
- Total Capital
- Total capital also shows a declining pattern from 2020 to 2023, falling from $99,132 million to $69,745 million. Unlike total debt, total capital stabilizes in 2024 with a slight increase to $70,469 million.
- Debt to Capital Ratio
- The debt to capital ratio decreases from 0.87 in 2020 to 0.79 in 2022, indicating a reduction in leverage during this period. Subsequently, the ratio rises to 0.85 in 2023 and further increases sharply to 0.95 in 2024, suggesting a significant increase in financial leverage toward the end of the period.
Overall, the data indicates a strategic reduction in both debt and capital from 2020 to 2023, accompanied by a lowering leverage ratio, which could reflect efforts to strengthen the balance sheet. The increase in debt and leverage ratio in 2024 points to a potential shift in financial strategy, possibly involving increased borrowing or changes in capital structure. This rising leverage could imply higher financial risk going forward if not managed carefully.
Debt to Capital (including Operating Lease Liability)
AbbVie Inc., debt to capital (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt and finance lease obligations | ||||||
Long-term debt and finance lease obligations, excluding current portion | ||||||
Total debt | ||||||
Current operating lease liabilities (included in Accounts payable and accrued liabilities) | ||||||
Noncurrent operating lease liabilities (included in Other long-term liabilities) | ||||||
Total debt (including operating lease liability) | ||||||
Stockholders’ equity | ||||||
Total capital (including operating lease liability) | ||||||
Solvency Ratio | ||||||
Debt to capital (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Capital (including Operating Lease Liability), Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Capital (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
An analysis of the financial data reveals the following trends and insights related to the company's debt and capital structure over the reported years:
- Total Debt (including operating lease liability)
- The total debt shows a decreasing trend from 87,063 million US dollars at the end of 2020 to 60,286 million US dollars by the end of 2023, indicating a reduction in debt load during this period. However, in 2024, there is a reversal with an increase to 68,019 million US dollars, suggesting a renewed borrowing or accumulation of liabilities.
- Total Capital (including operating lease liability)
- Total capital declined consistently from 100,139 million US dollars in 2020 to 70,646 million US dollars in 2023, indicating a contraction in the overall capital base. In 2024, capital remains relatively stable with a marginal increase to 71,344 million US dollars, signaling stabilization after the prior decreases.
- Debt to Capital Ratio (including operating lease liability)
- The debt to capital ratio decreases from 0.87 in 2020 to a low of 0.79 in 2022, reflecting a reduction in leverage and a strengthening of the capital structure. However, the ratio increases again to 0.85 in 2023 and further to 0.95 in 2024, indicating a significant rise in leverage and higher reliance on debt financing relative to total capital. This suggests an increasing risk profile in the most recent periods.
Overall, the company reduced its total debt and capital from 2020 through 2023, improving its leverage ratios until 2022. The subsequent years show increased debt levels and leverage ratios, signifying a shift toward higher indebtedness relative to capital. The stabilization of total capital alongside growing debt could point to strategic changes in financing or operational funding needs during the latest year analyzed.
Debt to Assets
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt and finance lease obligations | ||||||
Long-term debt and finance lease obligations, excluding current portion | ||||||
Total debt | ||||||
Total assets | ||||||
Solvency Ratio | ||||||
Debt to assets1 | ||||||
Benchmarks | ||||||
Debt to Assets, Competitors2 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Assets, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Assets, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt demonstrates a declining trend from 86,056 million USD at the end of 2020 to 59,385 million USD by the end of 2023, indicating a consistent reduction in debt levels over this period. However, in 2024, there is a noticeable increase to 67,144 million USD, suggesting a reversal in the previous downward trend and a potential increase in leverage or financing needs.
- Total Assets
- Total assets have gradually decreased over the five-year period, falling from 150,565 million USD in 2020 to 135,161 million USD in 2024. This steady decline suggests a contraction in the asset base, which could be due to asset sales, depreciation, or reduced investments.
- Debt to Assets Ratio
- The debt to assets ratio follows a downward trajectory from 0.57 in 2020 to 0.44 in 2023, reflecting an improving leverage position with decreasing reliance on debt relative to assets. Nevertheless, in 2024, this ratio increases to 0.50, which aligns with the rise in total debt while total assets remain relatively stable, indicating a slight deterioration in the company's leverage position compared to the previous year.
Debt to Assets (including Operating Lease Liability)
AbbVie Inc., debt to assets (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term borrowings | ||||||
Current portion of long-term debt and finance lease obligations | ||||||
Long-term debt and finance lease obligations, excluding current portion | ||||||
Total debt | ||||||
Current operating lease liabilities (included in Accounts payable and accrued liabilities) | ||||||
Noncurrent operating lease liabilities (included in Other long-term liabilities) | ||||||
Total debt (including operating lease liability) | ||||||
Total assets | ||||||
Solvency Ratio | ||||||
Debt to assets (including operating lease liability)1 | ||||||
Benchmarks | ||||||
Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Debt to Assets (including Operating Lease Liability), Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Debt to Assets (including Operating Lease Liability), Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The financial data over the five-year period reveals a distinct trend in the company's debt levels and asset base, alongside changes in leverage ratios.
- Total Debt (including operating lease liability)
- The total debt shows a decreasing trend from US$87,063 million in 2020 to US$60,286 million in 2023, indicating a significant reduction in the company's indebtedness. However, in 2024, there is a reversal with an increase to US$68,019 million, signaling a renewed rise in debt levels after several years of decline.
- Total Assets
- Total assets decreased steadily from US$150,565 million in 2020 to US$134,711 million in 2023. In 2024, the asset base stabilized with a slight increase to US$135,161 million, suggesting a plateau in asset levels after consistent contraction.
- Debt to Assets Ratio (including operating lease liability)
- This leverage ratio consistently declined from 0.58 in 2020 to 0.45 in 2023, demonstrating an improving balance sheet with reduced leverage risk. Nevertheless, in 2024, the ratio increased to 0.50, reflecting the impact of higher debt relative to assets that year, and marking a partial reversal of the deleveraging trend.
In summary, the company effectively reduced its total debt and improved its leverage position between 2020 and 2023, accompanied by a gradual decrease in total assets. The uptick in debt and leverage in 2024 indicates a shift in financial strategy or increased financing needs, while the stabilization in assets suggests a possible end to the prior contraction phase.
Financial Leverage
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Total assets | ||||||
Stockholders’ equity | ||||||
Solvency Ratio | ||||||
Financial leverage1 | ||||||
Benchmarks | ||||||
Financial Leverage, Competitors2 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Financial Leverage, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Financial Leverage, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The data indicates several notable trends in the company's financial position over the five-year period ending in 2024.
- Total Assets
- Total assets decreased gradually from 150,565 million US dollars in 2020 to 135,161 million US dollars in 2024. This represents a consistent downward trend, with the largest decline occurring between 2021 and 2023. The overall reduction reflects a contraction in the asset base over the period.
- Stockholders’ Equity
- Stockholders' equity initially increased from 13,076 million US dollars in 2020 to a peak of 17,254 million US dollars in 2022. However, a sharp decline occurred subsequently, with equity falling to 10,360 million US dollars in 2023 and further down to 3,325 million US dollars by 2024. This significant decrease in the last two years suggests increased losses, share buybacks, dividend payments exceeding earnings, or other equity reductions.
- Financial Leverage
- Financial leverage, defined as the ratio of total assets to stockholders’ equity, shows considerable volatility. It decreased from 11.51 in 2020 to 8.04 in 2022, indicating a reduction in leverage or increased equity relative to assets during that period. However, it reversed sharply after 2022, increasing dramatically to 13.00 in 2023 and reaching a very high level of 40.65 in 2024. This significant rise signals heightened financial risk, suggesting that liabilities have grown disproportionately compared to equity, potentially exposing the company to greater solvency pressures.
Overall, the declining asset base coupled with the severe reduction in equity and the concurrent surge in financial leverage in the most recent two years point to a challenging financial environment. The elevated leverage level in 2024 indicates increased reliance on debt financing, which may raise concerns about the company's financial stability and risk profile going forward.
Interest Coverage
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings attributable to AbbVie Inc. | ||||||
Add: Net income attributable to noncontrolling interest | ||||||
Add: Income tax expense | ||||||
Add: Interest expense | ||||||
Earnings before interest and tax (EBIT) | ||||||
Solvency Ratio | ||||||
Interest coverage1 | ||||||
Benchmarks | ||||||
Interest Coverage, Competitors2 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Interest Coverage, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Interest Coverage, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals significant fluctuations in key profitability and interest-related metrics over the five-year period analyzed.
- Earnings Before Interest and Tax (EBIT)
- EBIT showed a strong upward trend from 2020 to 2022, with an increase from 5,852 million US dollars in 2020 to a peak of 15,707 million US dollars in 2022. However, this positive momentum reversed sharply in the subsequent years, with EBIT declining to 8,474 million in 2023 and further to 6,524 million in 2024. This decline indicates a substantial reduction in operating profitability during the last two years.
- Interest Expense
- The interest expense remained relatively stable from 2020 through 2023, ranging from 2,230 to 2,454 million US dollars. However, in 2024, a noticeable increase occurred, with interest expense rising to 2,808 million US dollars, representing a material escalation in financing costs.
- Interest Coverage Ratio
- The interest coverage ratio, which measures the firm's ability to service its debt from operating profits, exhibited considerable variation. It improved significantly from 2.38 in 2020 to a high of 7.04 in 2022, reflecting strong earnings relative to interest charges. Subsequently, the ratio declined markedly to 3.81 in 2023 and further to 2.32 in 2024, reaching a value slightly below the 2020 level. This decline suggests a reduced margin of safety in meeting interest obligations and potentially increased financial risk.
In summary, the observed financial trends indicate a period of growth and strong operating performance until 2022, followed by a pronounced deterioration in earning capacity along with increased interest expenses, leading to notably weaker interest coverage in the most recent years. These patterns may imply challenges in maintaining profitability and financial stability moving forward.
Fixed Charge Coverage
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings attributable to AbbVie Inc. | ||||||
Add: Net income attributable to noncontrolling interest | ||||||
Add: Income tax expense | ||||||
Add: Interest expense | ||||||
Earnings before interest and tax (EBIT) | ||||||
Add: Operating lease cost | ||||||
Earnings before fixed charges and tax | ||||||
Interest expense | ||||||
Operating lease cost | ||||||
Fixed charges | ||||||
Solvency Ratio | ||||||
Fixed charge coverage1 | ||||||
Benchmarks | ||||||
Fixed Charge Coverage, Competitors2 | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Danaher Corp. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Fixed Charge Coverage, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Fixed Charge Coverage, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
- Earnings before fixed charges and tax
- The earnings before fixed charges and tax showed a significant increase from 6,044 million US dollars in 2020 to a peak of 15,908 million US dollars in 2022. However, after reaching this high, there was a notable decline in 2023 to 8,663 million US dollars, followed by a further decrease to 6,720 million US dollars in 2024. This pattern indicates strong growth in the initial years, succeeded by a sharp downturn in earnings in the most recent years.
- Fixed charges
- Fixed charges remained relatively stable from 2020 through 2023, ranging between approximately 2,400 and 2,650 million US dollars. In 2024, fixed charges increased notably to 3,004 million US dollars. This rise in fixed charges in 2024 contrasts with the earlier steady trend and may have implications on fixed charge coverage.
- Fixed charge coverage ratio
- The fixed charge coverage ratio exhibited a strong upward trend from 2.28 in 2020 to a peak of 6.54 in 2022, reflecting an improving ability to cover fixed charges with earnings. Subsequently, the coverage ratio declined substantially, dropping to 3.59 in 2023 and further to 2.24 in 2024. The reduction in this ratio aligns with the decline in earnings and the increased fixed charges observed in the most recent year, indicating a decreased margin of safety in meeting fixed financial obligations.